Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

July 05, 2015 4:20 PM ET


Company Overview of GenoMed, Inc.

Company Overview

GenoMed, Inc. develops and manufactures drugs using medical genomics. The company focuses in the field of preventive molecular medicine. It identifies a disease gene without any existing therapy for drug discovery; uses existing drugs for new clinical indications; and conducts gene-based diagnostic tests. The company offers SNPnet, a set of single nucleotide polymorphisms used to locate disease genes; and clinical outcomes improvement program for sickle cell diseases, kidney failure due to type II diabetes, kidney failure due to high blood pressure, emphysema, and poor circulation due to high blood pressure. The company also engages in clinical trial drugs for cancer, HIV, SARS, influenza, h...

620 South Lake Street

Suite 5

Leesburg, FL 34748

United States

Founded in 2001

6 Employees



Key Executives for GenoMed, Inc.

Chairman of the Board, Chairman of Scientific Advisory Board, Chief Executive Officer, President, Chief Administrative Officer, Chief Medical Officer, Treasurer, Member of Business Development Advisory Board and Member of Ethical Legal & Social Issues (ELSI) Committee
Age: 62
Chief Financial Officer
Chief of Bioinformatics
Age: 32
Chief Technical Officer
Corporate Secretary and Director
Age: 71
Compensation as of Fiscal Year 2015.

GenoMed, Inc. Key Developments

GenoMed Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2013; Reiterates Earnings Guidance for the Year 2013

GenoMed Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2013. The company's second quarter net sales were $107.0 million, compared to $96.0 million last year, representing an 11.5% increase. Net income for the quarter was $7.4 million, or $0.08 per diluted share, as compared to $19.0 million, or $0.21 per diluted share, for the second quarter of 2012. Non-GAAP earnings per diluted share were $0.21 and $0.20 for the quarters ending June 30, 2013 and 2012, respectively. The non-GAAP earnings per diluted share excludes the after-tax effect of the provisions for litigation losses. Non-GAAP adjusted EBITDA for the quarter was 34.0% of net sales, compared to 36.1% for the same period last year. The Medical Device Excise Tax, which was not in effect in 2012, reduced adjusted EBITDA by 1.6% for the second quarter of 2013. Operating income was $11,192,000 against $30,565,000 a year ago. Income before income taxes was $10,971,000 against $30,261,000 a year ago. Adjusted EBITDA was $36,338,000 against $34,665,000 a year ago. EBITDA was $15,569,000 against $34,715,000 a year ago. For the six months period, the company reported sales of $212,027,000 against $190,694,000 a year ago. Operating income was $40,423,000 against $58,623,000 a year ago. Income before income taxes was $40,481,000 against $58,544,000 a year ago. Net income was $27,317,000 or $0.29 per diluted share against $36,577,000 or $0.40 per diluted share a year ago. Net cash provided by operating activities was $27,256,000 against $34,880,000 a year ago. Purchases of property and equipment were $12,956,000 against $11,849,000 a year ago. Adjusted EBITDA was $71,844,000 against $68,636,000 a year ago. Non-GAAP diluted EPS was $0.43 against $0.40 a year ago. EBITDA was $49,643,000 against $67,370,000 a year ago. The company reiterated its revenue guidance and non-GAAP diluted earnings per share guidance for 2013. For 2013, the company continues to expect full-year revenue to be approximately $432 million and non-GAAP annual diluted earnings per share, which excludes provisions for litigation losses, to be approximately $0.81.

Similar Private Companies By Industry

Company Name Region
Angiorad, L.L.C. United States
BioAssets Development Corporation, Inc. United States
Phylos, Inc. United States
X-Chem, Inc. United States
BioInspire Technologies, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GenoMed, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at